<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04896112</url>
  </required_header>
  <id_info>
    <org_study_id>LNK-1002-01</org_study_id>
    <secondary_id>IND 153144</secondary_id>
    <nct_id>NCT04896112</nct_id>
  </id_info>
  <brief_title>A Study of LNK01002 in Patients With Primary (PMF) or Secondary Myelofibrosis (PV-MF, ET-MF) or Acute Myeloid Leukemia</brief_title>
  <official_title>An Open-Label, Multicenter, Phase I Study to Evaluate the Safety, Pharmacokinetics and Preliminary Efficacy of LNK01002 in Patients With Malignant Myeloid Hematologic Neoplasms</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lynk Pharmaceuticals Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Lynk Pharmaceuticals Co., Ltd</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This multicenter, open-label, phase 1 study designed to evaluate safety and tolerability of&#xD;
      multi-kinase inhibitor LNK01002 in patients with primary myelofibrosis (MF), or MF due to&#xD;
      polycythemia vera (PV-MF), or essential thrombocythemia (ET-MF), or with acute myeloid&#xD;
      leukemia (AML).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase I, open-label, dose-finding study of the triple kinase inhibitor LNK01002 in&#xD;
      patients with myelofibrosis (MF). The study consists of two periods: the dose escalation,&#xD;
      main period and a dose expansion period. In the dose escalation period, successive cohorts of&#xD;
      patients with MF will be enrolled to establish the maximum tolerated dose. In the dose&#xD;
      expansion period (dose-confirmation phase), three cohorts of patients will be enrolled: AML&#xD;
      patients with confirmed FLT3-ITD mutations, AML patients without FLT3-ITD mutations, and&#xD;
      patients with primary MF or PV/ET-MF.&#xD;
&#xD;
      The safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary clinical&#xD;
      activity of LNK01002 in patients with myelofibrosis/AML will be evaluated.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 8, 2021</start_date>
  <completion_date type="Anticipated">December 23, 2023</completion_date>
  <primary_completion_date type="Anticipated">October 23, 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>An Open-Label, Multicenter, Phase I Study to Evaluate the Safety, Pharmacokinetics and Preliminary Efficacy of LNK01002</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assessing the safety and tolerability of LNK01002 in patients with myelofibrosis</measure>
    <time_frame>31 days</time_frame>
    <description>Assessed by monitoring the frequency, duration and severity of adverse events and serious adverse events.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessing maximum tolerated dose (MTD) and/or recommended phase II dose (RP2D) of LNK01002 in patients with myelofibrosis</measure>
    <time_frame>31 days</time_frame>
    <description>Maximum tolerated dose (MTD) and/or recommended phase II dose (RP2D) will be assessed based on the safety profile by the SRC</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessing the preliminary antitumor activity of LNK01002</measure>
    <time_frame>24 Weeks</time_frame>
    <description>The preliminary antitumor activity will be analyzed in patients with different types of malignant myeloid hematologic neoplasms by response rate using bone marrow and hematologic analyses (MF/AML) or by the MF Symptom Assessment Scale and spleen volume by MRI (MF).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Measurement of pharmacokinetic (PK) parameter, AUC, in MF, PV-MF or ET-MF patients</measure>
    <time_frame>Day 1, Day 2, and Day 15</time_frame>
    <description>Measurement will be using extensive PK sampling</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of pharmacokinetic (PK) parameter, Cmax, in MF, PV-MF or ET-MF patients</measure>
    <time_frame>Day 1, Day 2, and Day 15</time_frame>
    <description>Measurement will be using extensive PK sampling</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of pharmacokinetic (PK) parameter, Tmax, in MF, PV-MF or ET-MF patients</measure>
    <time_frame>Day 1, Day 2, and Day 15</time_frame>
    <description>Measurement will be using extensive PK sampling</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of pharmacokinetic (PK) parameter, CL/F, in MF, PV-MF or ET-MF patients</measure>
    <time_frame>Day 1, Day 2, and Day 15</time_frame>
    <description>Measurement will be using extensive PK sampling</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of pharmacokinetic (PK) parameter, T1/2, in MF, PV-MF or ET-MF patients</measure>
    <time_frame>Day 1, Day 2, and Day 15</time_frame>
    <description>Measurement will be using extensive PK sampling</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of pharmacokinetic (PK) parameter, Vz/F, in MF, PV-MF or ET-MF patients</measure>
    <time_frame>Day 1, Day 2, and Day 15</time_frame>
    <description>Measurement will be using extensive PK sampling</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of pharmacokinetic (PK) parameter, MRT, in MF, PV-MF or ET-MF patients</measure>
    <time_frame>Day 1, Day 2, and Day 15</time_frame>
    <description>Measurement will be using extensive PK sampling</description>
  </secondary_outcome>
  <number_of_arms>9</number_of_arms>
  <enrollment type="Anticipated">93</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <condition>Primary Myelofibrosis</condition>
  <condition>Post-polycythemia Vera Myelofibrosis</condition>
  <condition>Post-essential Thrombocythemia Myelofibrosis</condition>
  <arm_group>
    <arm_group_label>Patient with Malignant Myeloid Hematologic Neoplasms treated with LNK01002 15 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of LNK01002 15 mg; followed by a 3-day observation period then 15mg BID in 28-day treatment cycles</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients with Malignant Myeloid Hematologic Neoplasms treated with LNK01002 30 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LNK01002 30 mg twice daily (BID), followed by a 3-day observation period then 30 mg BID in 28-day treatment cycles</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients with Malignant Myeloid Hematologic Neoplasms treated with LNK01002 45 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LNK01002 45 mg BID, followed by a 3-day observation period then 45 mg BID in 28-day treatment cycles</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients with Malignant Myeloid Hematologic Neoplasms treated with LNK01002 60 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LNK01002 60 mg BID, followed by a 3-day observation period then 60 mg BID in 28-day treatment cycles</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients with Malignant Myeloid Hematologic Neoplasms treated with LNK01002 80 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LNK01002 80 mg BID, followed by a 3-day observation period then 80 mg BID in 28-day treatment cycles</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients with Malignant Myeloid Hematologic Neoplasms treated with LNK01002 100 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LNK01002 100 mg BID, followed by a 3-day observation period then 100 mg BID in 28-day treatment cycles</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients with Acute Myeloid Leukemia With Mutant FLT3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LNK01002 at the RP2D dose in 28-day treatment cycles</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients with Malignant Myeloid Hematologic Neoplasms Without Mutant FLT3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LNK01002 at the RP2D dose in 28-day treatment cycles</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients with Primary or Secondary Myelofibrosis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LNK01002 at the RP2D dose in 28-day treatment cycles</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LNK01002</intervention_name>
    <description>LNK01002 will be administrated orally.</description>
    <arm_group_label>Patient with Malignant Myeloid Hematologic Neoplasms treated with LNK01002 15 mg</arm_group_label>
    <arm_group_label>Patients with Acute Myeloid Leukemia With Mutant FLT3</arm_group_label>
    <arm_group_label>Patients with Malignant Myeloid Hematologic Neoplasms Without Mutant FLT3</arm_group_label>
    <arm_group_label>Patients with Malignant Myeloid Hematologic Neoplasms treated with LNK01002 100 mg</arm_group_label>
    <arm_group_label>Patients with Malignant Myeloid Hematologic Neoplasms treated with LNK01002 30 mg</arm_group_label>
    <arm_group_label>Patients with Malignant Myeloid Hematologic Neoplasms treated with LNK01002 45 mg</arm_group_label>
    <arm_group_label>Patients with Malignant Myeloid Hematologic Neoplasms treated with LNK01002 60 mg</arm_group_label>
    <arm_group_label>Patients with Malignant Myeloid Hematologic Neoplasms treated with LNK01002 80 mg</arm_group_label>
    <arm_group_label>Patients with Primary or Secondary Myelofibrosis</arm_group_label>
    <other_name>LNK-1000318</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age: 18 years old or older, male or female.&#xD;
&#xD;
          2. Patients must have histologically or cytologically confirmed tumors of the following&#xD;
             types.&#xD;
&#xD;
          3. Dose Escalation Phase: Patients with PMF, PV/ET-MF&#xD;
&#xD;
               1. Intermediate or high-risk primary myelofibrosis, post-polycythemia vera&#xD;
                  myelofibrosis, or post-essential thrombocythaemia myelofibrosis which failed&#xD;
                  standard treatment.&#xD;
&#xD;
               2. Symptomatic splenomegaly&#xD;
&#xD;
               3. Not undergone splenectomy or splenic radiation therapy within 6 months prior to&#xD;
                  screening.&#xD;
&#xD;
          4. Dose expansion phase: Patients with PMF, PV/ET-MF who relapsed or are intolerant to&#xD;
             standard treatment, and relapsed/refractory AML&#xD;
&#xD;
          5. Platelet count ≥ 100 × 10e9/L within 14 days before study drug administration&#xD;
&#xD;
          6. Absolute neutrophil count (ANC) ≥ 1.5 × 10e9/L within 14 days before study drug&#xD;
             administration&#xD;
&#xD;
          7. Women of childbearing potential negative pregnancy test at screening. Female patients&#xD;
             of childbearing potential, or male patients and their partners should agree to&#xD;
             effective contraception from signing ICF until 6 months after the last dose of study&#xD;
             drug.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Patients who meet any of the following exclusion criteria will be excluded from the&#xD;
        clinical study:&#xD;
&#xD;
          1. Allergic to any component of LNK01002.&#xD;
&#xD;
          2. Serum total bilirubin greater than 1.5 times the upper limit of the normal (ULN)&#xD;
             reference range, except patients diagnosed as Gilbert's disease&#xD;
&#xD;
          3. ALT or AST higher than 3 times the ULN reference range without hepatic involvement by&#xD;
             leukemia, which are excluded if higher than 5 times the ULN&#xD;
&#xD;
          4. Glomerular filtration rate or estimated creatinine clearance &lt; 50 mL/min according to&#xD;
             the Cockcroft-Gault formula;&#xD;
&#xD;
          5. Serum amylase or lipase levels higher than the ULN and considered clinically&#xD;
             significant&#xD;
&#xD;
          6. International normalized ratio (INR) or partial activated prothrombin time (aPTT)&#xD;
             above 1.5 times the ULN reference range&#xD;
&#xD;
          7. Known history of clinically significant liver disease, including viral or other&#xD;
             hepatitis:&#xD;
&#xD;
             a) Patients with hepatitis B or hepatitis C may be enrolled if they have a negative&#xD;
             polymerase chain reaction (PCR)&#xD;
&#xD;
          8. Known human immunodeficiency virus (HIV) infection;&#xD;
&#xD;
          9. Clinically significant cardiovascular diseases, including acute myocardial infarction,&#xD;
             unstable angina, coronary artery bypass surgery within 6 months before enrollment,&#xD;
             congestive heart failure with New York Heart Association (NYHA) classification of III&#xD;
             or above, left ventricular ejection fraction (LVEF) &lt; 50%, or uncontrolled&#xD;
             hypertension, cardiac arrhythmia;&#xD;
&#xD;
         10. Patients with history or presence of clinically relevant non-malignant CNS disease&#xD;
             requiring treatment&#xD;
&#xD;
         11. Patients who have received systemic antineoplastic therapy or radiotherapy within 2&#xD;
             weeks prior to start of study treatment:&#xD;
&#xD;
         12. Patients who have received hematopoietic stem cell transplantation (HSCT) within 60&#xD;
             days prior to the start of study treatment, or are receiving immunosuppressive therapy&#xD;
             after HSCT at screening, or have graft-versus-host disease (GVHD) requiring drug&#xD;
             control:&#xD;
&#xD;
         13. Received anti-tumor Chinese herbal medicine treatment within 1 week before the start&#xD;
             of study treatment;&#xD;
&#xD;
         14. Received CYP3A substrates, CYP2B6 substrates, CYP2C substrates, OATP1B3 substrates,&#xD;
             UGT1A1 inhibitors, or UGT1A3 inhibitors less than one week or 5 half-lives (whichever&#xD;
             is longer) prior to the start of study treatment;&#xD;
&#xD;
         15. Uncontrolled, active infections requiring intravenous antibiotic treatment;&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sherry Weigand, M.D., Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>Lynk Pharmaceuticals Co., Ltd</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Peter Langecker, M.D.</last_name>
    <phone>408-656-9855</phone>
    <email>plangecker@clinipace.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sherry Weigand, M.D., Ph.D.</last_name>
    <phone>617-678-5412</phone>
    <email>sweigand1@lynkpharma.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Revive Research Institute</name>
      <address>
        <city>Farmington Hills</city>
        <state>Michigan</state>
        <zip>48334</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Samuel Ceckowski</last_name>
      <phone>248-721-9539</phone>
      <email>sceckowski@rev-research.com</email>
    </contact>
    <contact_backup>
      <last_name>Balaraman</last_name>
    </contact_backup>
    <investigator>
      <last_name>Savitha Balaraman, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Revive Research Institute</name>
      <address>
        <city>Sterling Heights</city>
        <state>Michigan</state>
        <zip>48314</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mohammed Ali</last_name>
      <phone>248-238-6010</phone>
      <email>mali@rev-research.com</email>
    </contact>
    <investigator>
      <last_name>Adil Akhtar, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>May 8, 2021</study_first_submitted>
  <study_first_submitted_qc>May 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 21, 2021</study_first_posted>
  <last_update_submitted>June 5, 2021</last_update_submitted>
  <last_update_submitted_qc>June 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acute Myeloid Leukemia</keyword>
  <keyword>Primary Myelofibrosis</keyword>
  <keyword>Post-polycythemia Vera Myelofibrosis</keyword>
  <keyword>Post-essential Thrombocythemia Myelofibrosis</keyword>
  <keyword>Myeloid malignancies</keyword>
  <keyword>Myelofibrosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Polycythemia Vera</mesh_term>
    <mesh_term>Primary Myelofibrosis</mesh_term>
    <mesh_term>Polycythemia</mesh_term>
    <mesh_term>Thrombocytosis</mesh_term>
    <mesh_term>Thrombocythemia, Essential</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

